

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH SEPTEMBER, 2004**

Unaudited			(Rs. Lakhs)		
3 months ended 30.09.2004	3 months ended 30.09.2003		Unaudited 9 months ended 30.09.2004	Unaudited 9 months ended 30.09.2003	Audited Year ended 31.12.2003
40094	33733	Sales	117940	94511	119169
2730	2542	Less: Excise Duty on Sales	8604	7235	9011
37364	31191	Net Sales	109336	87276	110158
533	903	Other Income	1771	2689	3462
601	510	Interest Income (net)	2148	1417	1975
38498	32604	Total Income	113255	91382	115595
		Materials Consumed			
(507)	(171)	(Increase) / decrease in stock-in-trade	694	2417	(451)
		Consumption of raw and packing materials and purchase of finished goods			
15817	14245	Total Materials Consumed	46740	38445	49885
15310	14074	Staff Cost	47434	40862	49434
3762	3434	Other Expenditure	11325	10196	13005
6644	6050	Recovery of Expenses	19140	17048	23911
(153)	(275)	Total Expenditure	(514)	(809)	(1004)
25564	23283	Depreciation	77385	67297	85346
417	427	Profit before Tax and Exceptional Items	1233	1304	1793
12517	8894	Provision for Taxation - Current tax	34637	22781	28456
4312	2885	- Deferred tax	11902	7660	9258
297	235	Net Profit after Tax before Exceptional Items	523	591	1012
7908	5774	Exceptional Items (net of tax)	22212	14530	18186
9342	-	Net Profit	8734	1229	(963)
17250	5774	Paid-up Equity Share Capital (Face value per share Rs. 10)	30946	15759	17223
7448	7448	Share Capital to be issued, consequent to the merger of BWIL with the Company	7448	7448	7448
1284	-	Total Share Capital	1284	-	-
8732	7448	Reserves excluding Revaluation Reserves	8732	7448	7448
9.1	7.8	Earnings per Share before Exceptional Items (Rs.)	25.4	19.5	24.4
19.8	7.8	Earnings per Share / Diluted Earnings per Share (Rs.)	35.4	21.2	23.1
		Aggregate of Non-promoter Shareholding :			
44405058	38109750	Number of Shares	44405058	38109750	38109750
51%	51%	% of Shareholding	51%	51%	51%

1. In view of the merger of Burroughs Wellcome (India) Limited (BWIL) with the Company with effect from 1st January, 2004, the financial results for the three months and nine months ended 30th September, 2004 include the financial results of BWIL and are, therefore, not comparable with the results of the corresponding period last year. The figures for 2003 have been regrouped wherever necessary.

For information, the results for the nine-month period ended 30th September, 2004 on a comparable basis are as follows:

	9 months ended 30.09.2004	9 months ended 30.09.2003
	Rs. Lakhs	Rs. Lakhs
Net Sales	109336	101921
Profit before Tax and Exceptional Items	34637	29107
Provision for Taxation	12425	10543
Net Profit after Tax before Exceptional Items	22212	18564

2. Exceptional Items comprise of sale of a plot located at Worli and expenses connected therewith, costs of separation and retirement benefits for the management staff at the Bangalore factory and stamp duties and other costs associated with the merger of BWIL with the Company.
3. In respect of the audit qualification in the financial statements of BWIL for the year ended 31st December, 2003, with regard to the Drugs Prices Equalisation Account (DPEA) demand of Rs. 191 Lakhs and interest thereon, in respect of a bulk drug procured by BWIL during the period 1981 to 1983, which, according to eminent counsel, is not sustainable, the Company maintains its stand that no provision is necessary. The audit qualification has been retained, since the matter is subjudice.
4. There were no Investor complaints pending as at the beginning of the quarter. The Company has received 46 complaints from the Investors during the quarter and all of them have since been resolved.
5. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 29th October, 2004. The statutory auditors have carried out a limited review of the results for the three months ended 30th September, 2004.

By Order of the Board

S. Kalyanasundaram
Managing Director

29th October, 2004